<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932618</url>
  </required_header>
  <id_info>
    <org_study_id>071102</org_study_id>
    <secondary_id>2016-001477-33</secondary_id>
    <nct_id>NCT02932618</nct_id>
  </id_info>
  <brief_title>BAX 111 rVWF in Pediatrics</brief_title>
  <official_title>A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxalta Innovations GmbH, now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in pediatric participants (&lt;18 years of age) with severe hereditary
      von Willebrand disease (VWD) is:

        1. To assess the efficacy, safety, and tolerability of recombinant von Willebrand Factor
           (rVWF), with or without ADVATE, in the treatment and control of nonsurgical bleeding
           events

        2. To assess the efficacy and safety of rVWF with ADVATE during elective or emergency
           surgery

        3. To determine the pharmacokinetic (PK) profile of rVWF
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      18 JUN 2020: The temporary enrollment stop of new patients into this study due to the
      COVID-10 pandemic has been lifted in one or more countries/sites, and the study is now again
      enrolling new patients. However, some countries/sites may still have paused the enrollment of
      new patients due to the pandemic.

      23 APRIL 2020: Enrollment of new patients into this study has been paused due to the COVID-19
      situation. The duration of this pause is dependent on the leveling and control of the
      COVID-19 pandemic.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemostatic Efficacy</measure>
    <time_frame>Within 24 hours after the last infusion of study drug following the onset of the bleeding episode (if/when the severity and/or duration of the bleeding requires the infusion of the study drug)</time_frame>
    <description>Treatment success for rVWF-treated nonsurgical bleeding episodes (using a 4-point scale: Excellent, Good, Moderate, None).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Nonsurgical Bleeding Episodes with an Efficacy Rating of 'Excellent' or 'Good'</measure>
    <time_frame>Throughout the study duration of approximately 6 years</time_frame>
    <description>If/when the severity and/or duration of the bleeding requires the infusion of the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions per Bleeding Episode</measure>
    <time_frame>Throughout the study duration of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Recombinant Von Willebrand Factor (rVWF), Units per Bleeding Episode</measure>
    <time_frame>Throughout the study duration of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ADVATE Units (if needed), per Bleeding Episode</measure>
    <time_frame>Throughout the study duration of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elective or Emergency Surgery: Assessment of Hemostatic Efficacy - Immediately After Surgery</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Assessed by by the operating surgeon, based on a 4-point ordinal scale: Excellent, Good, Moderate, None.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elective or Emergency Surgery: Overall Assessment of Hemostatic Efficacy 24 hours After the Last Perioperative Infusion of rVWF</measure>
    <time_frame>24 hours after last perioperative rVWF infusion</time_frame>
    <description>Assessed by the Investigator (hematologist) on a 4-point ordinal scale: Excellent, Good, Moderate, None.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elective or emergency surgery: Overall Assessment of Hemostatic Efficacy Day 7 post-operative</measure>
    <time_frame>Post-operative Day 7</time_frame>
    <description>Assessed by the Investigator (hematologist) on a 4-point ordinal scale: Excellent, Good, Moderate, None.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elective or emergency surgery: Overall Assessment of Hemostatic Efficacy Day 14 post-operative</measure>
    <time_frame>Post-operative Day 14</time_frame>
    <description>Assessed by the Investigator (hematologist) on a 4-point ordinal scale: Excellent, Good, Moderate, None.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Thrombotic Events</measure>
    <time_frame>Throughout the study period of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe Hypersensitivity Reactions</measure>
    <time_frame>Throughout the study period of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Neutralizing Antibodies to von Willebrand Factor (VWF) and Factor VIII (FVIII)</measure>
    <time_frame>Throughout the study period of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Total Binding Antibodies to von Willebrand Factor (VWF)</measure>
    <time_frame>Throughout the study period of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Antibodies to Chinese Hamster Ovary (CHO) Proteins, Murine Immunoglobulin G (IgG), and rFurin</measure>
    <time_frame>Throughout the study period of approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration/Time Curve From 0 to 96 Hours Post-Infusion (AUC0-96h)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration/Time Curve From Time 0 to Infinity (AUC0-inf)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximal Plasma Concentration (Tmax)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
    <description>Tmax will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Plasma Concentration (Cmax)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
    <description>Cmax will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery (IR)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-vivo Recovery (IVR)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Phase Half-life (T1/2)</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) for VWF:RCo, VWF:Ag and VWF:CB</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration/Time Curve from 0 to 96 Hours Post-infusion (AUC0-96h) for VWF:Ag and VWF:CB</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
    <description>von Willebrand factor: antigen (VWF:Ag); von Willebrand factor: collagen binding capacity (VWF:CB).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration/Time Curve From 0 to 96 Hours Post-infusion (AUC0-96h) for Factor VIII (FVIII) Activity</measure>
    <time_frame>Within 30 minutes prior to infusion and post infusion at: SEQUENCE 1: 1, 24, 72 hours; SEQUENCE 2: 0.25, 12, and 48 hours; SEQUENCE 3: 6, 30, and 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>On-demand Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment for non-surgical bleeding episodes over a 12 to 18-month period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elective Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12-24 hours prior to surgery and within 3 hours of surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emergency Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 3 hours prior to surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>von Willebrand factor (Recombinant)</intervention_name>
    <description>Lyophilized powder and solvent to prepare solution for injection.</description>
    <arm_group_label>Elective Surgery</arm_group_label>
    <arm_group_label>Emergency Surgery</arm_group_label>
    <arm_group_label>On-demand Treatment</arm_group_label>
    <other_name>VONVENDI</other_name>
    <other_name>rVWF</other_name>
    <other_name>BAX111</other_name>
    <other_name>BAX 111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic Factor (Recombinant)</intervention_name>
    <description>Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.</description>
    <arm_group_label>Elective Surgery</arm_group_label>
    <arm_group_label>Emergency Surgery</arm_group_label>
    <arm_group_label>On-demand Treatment</arm_group_label>
    <other_name>ADVATE</other_name>
    <other_name>Recombinant Factor VIII</other_name>
    <other_name>rFVIII</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of severe von Willebrand disease (VWD) (defined as von Willebrand factor:
             ristocetin cofactor [VWF:RCo] less than [&lt;] 20 percent [%]):

               1. Type 1 (VWF:RCo &lt; 20 International Units per deciliter [IU/dL]); or

               2. Type 2A (VWF:RCo &lt; 20 IU/dL), Type 2B (as diagnosed by genotype), Type 2N (Factor
                  VIII coagulation activity [FVIII:C] &lt; 10 % and historically documented genetics),
                  Type 2M; or

               3. Type 3 (VWF:Ag less than or equal to [=&lt;] 3 IU/dL).

          -  Age 0 to &lt; 18 years at the time of Screening.

          -  The participant has provided assent (if appropriate) and legally authorized
             representative(s) has provided informed consent.

          -  If female of childbearing potential, participant presents with a negative serum
             pregnancy test.

          -  If applicable, participant agrees to employ adequate birth control measures for the
             duration of the study.

          -  The participant and/or the legally authorized representative are willing and able to
             comply with the requirements of the protocol, which should also be confirmed based on
             a pre-screening evaluation held between the Investigator and the Sponsor, to ensure no
             eminent risk is present that could challenge the participants compliance with the
             study requirements.

        Additional inclusion criteria for previously treated participants and participants
        undergoing surgery are as follows:

          -  Unable to tolerate or are inadequately responsive to deamino-delta-D-arginine
             vasopressin.

          -  The participant has had a minimum of 1 documented bleed requiring VWF coagulation
             factor replacement therapy (i.e. treatment with a VWF product) during the previous 12
             months prior to enrollment and overall historically 3 or more exposure days (EDs) to
             plasma-derived von Willebrand disease (pdVWF).

        Additional inclusion criterion for previously untreated participants are as follows:

          -  The participant has not received prior VWF coagulation factor replacement therapy.

          -  Pediatric participants in the continuation study (SHP677-304 [NCT03879135]) that
             require elective or emergency surgical/invasive treatment during their participation
             in the continuation study may be considered for enrollment in this study's surgery arm
             to receive treatment with the study drug (rVWF) for peri-operative management of
             surgery related bleeds/bleeding tendency, if they continue meeting all other
             eligibility criteria for the surgery arm in this Pediatric On-Demand and Surgery
             study, 071102.

        Exclusion Criteria:

          -  Diagnosis of pseudo-VWD or another hereditary or acquired coagulation disorder (eg,
             qualitative and quantitative platelet disorders or elevated prothrombin time
             [PT]/international normalized ratio [INR] greater than [&gt;] 1.4).

          -  History or presence of a VWF inhibitor at Screening.

          -  History or presence of a Factor VIII (FVIII) inhibitor with a titer greater than or
             equal [&gt;=] 0.4 Bethesda units (BU) (by Nijmegen assay) or &gt;= 0.6 BU (by Bethesda
             assay).

          -  Documented history of a VWF: RCo half-life &lt; 6 hours.

          -  Known hypersensitivity to any of the components of the study drug, such as mouse or
             hamster proteins.

          -  Medical history of immunological disorders, excluding seasonal allergic
             rhinitis/conjunctivitis/asthma, food allergies, or animal allergies.

          -  Medical history of a thromboembolic event.

          -  Human immunodeficiency virus (HIV) positive, with an absolute CD4 count &lt; 200/ cubic
             millimeter (mm^3).

          -  In the judgment of the Investigator, the participant has another clinically
             significant concomitant disease (e.g. uncontrolled hypertension, cancer) that may pose
             additional risks for the participant.

          -  Diagnosis of significant liver disease, as evidenced by, but not limited to, any of
             the following: serum alanine aminotransferase (ALT) of 5 times the upper limit of
             normal; hypoalbuminemia; portal vein hypertension (e.g. presence of otherwise
             unexplained splenomegaly, history of esophageal varices) or liver cirrhosis classified
             as Child B or C.

          -  Diagnosis of renal disease, with a serum creatinine level &gt;= 2.5 milligram per
             deciliter (mg/dL).

          -  Immunomodulatory drug treatment other than anti-retroviral chemotherapy (e.g.
             α-interferon, or corticosteroid agents at a dose equivalent to hydrocortisone greater
             than 10 milligram per day [mg/day] (excluding topical treatment [e.g. ointments, nasal
             sprays]), within 30 days prior to signing the informed consent (or assent, if
             appropriate).

          -  If female, participant is pregnant or lactating at the time informed consent (or
             assent, if appropriate) is obtained.

          -  Participant has participated in another clinical study involving an investigational
             product (IP), other than recombinant von Willebrand Factor (rVWF) with or without
             ADVATE, or investigational device within 30 days prior to enrollment or is scheduled
             to participate in another clinical study involving an IP other than rVWF or
             investigational device during the course of this study.

          -  Participant's legal representative is a family member or employee of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>clinicaltransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>michael.wang@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>mfguerre@cnmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Guerrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>twynn@peds.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Tung Wynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>jroberts@ilbcdi.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>sgupta@ihtc.org</email>
    </contact>
    <investigator>
      <last_name>Sweta Gupta, MD, MS, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Affiliate Clinic at Novant Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>pcbryant@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Bryant Paulette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Wake Forest Unversity</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>eric.mullins@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Eric Mullins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>sanjay.ahuja@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Ahuja, MD, MSc, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>Amy.Dunn@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Amy Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>raffini@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Raffini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>bergmans@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Shayla Bergmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer and Hematology Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>lxvenkat@txch.org</email>
    </contact>
    <investigator>
      <last_name>Lakshmi Srivaths, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>jessica.meznarich@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Meznarich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Center for Bleeding Disorders</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>shawn.jobe@bcw.edu</email>
    </contact>
    <investigator>
      <last_name>Shawn Jobe, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>werner.streif@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Werner Streif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AKH - Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>christoph.male@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Male, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>veerle.labarque@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Veerle Labarque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>613 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>jblatny@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Blatny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>brigitte.pan-petesch@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Pan-Petesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>yoann.huguenin@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Yoann Huguenin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Est- Hôpital Louis Pradel</name>
      <address>
        <city>Bron cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>lucia.rugeri@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Lucia Rugeri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU CAEN - Hôpital de la Côte de Nacre</name>
      <address>
        <city>Caen cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>borelderlon-a@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Annie Borel-Derlon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Sud - Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>roseline.doiron@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Roseline D oiron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cardiologique - CHU Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>sophie.susen@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Susen, MD, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes Site Hotel Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>marc.trossaert@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Trossaert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - Enfants Malades</name>
      <address>
        <city>Paris cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>annie.harroche@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Annie Harroche-Angel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>hassenpflug@uke.de</email>
    </contact>
    <investigator>
      <last_name>Wolf-Achim Hassenpflug, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Werlhof-Institut GmbH</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>cwe@werlhof-institut.de</email>
    </contact>
    <investigator>
      <last_name>Cornelia Wermes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>wieland.ivonne@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Ivonne Wieland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>castaman@aou-careggi.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Giancarlo Castaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>flora.peyvandi@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Flora Peyvandi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pediatrica Santobono Pausillipon</name>
      <address>
        <city>Napoli</city>
        <zip>80122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>mischiavulli@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michele Schiavulli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>matteo.luciani@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Matteo Luciani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>m.cnossen@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Marjon Cnossen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBEI HPE Altai State Medical University of MoH and SD</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>amamaev@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Andrey Mamaev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SAIH &quot;Kemerovo Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>mvkosinova@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Marina Kosinova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FSBI of Science &quot;Kirov Scientific and Research Institute of Hematology and Blood Transfusion of FMBA</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>timofeevamargaret@list.ru</email>
    </contact>
    <investigator>
      <last_name>Margarita Timofeeva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>marco_pas@gva.es</email>
    </contact>
    <investigator>
      <last_name>Pascual Marco Vera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>cid_ana@gva.es</email>
    </contact>
    <investigator>
      <last_name>Ana Rosa Cid Haro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>bulent.zulfikar@istanbulmedicare.com</email>
    </contact>
    <investigator>
      <last_name>Osman Bulent Zulfikar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>KAAN.KAVAKLI@EGE.EDU.TR</email>
    </contact>
    <investigator>
      <last_name>Ramazan Kavakli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis Univ. Med. Fac.</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>calbayrak@omu.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Canan Albayrak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SI Institute of Blood Pathology and Transfusion Medicine of NAMSU</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>lstasyshyn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oleksandra Stasyshyn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

